Saving lives by defeating ARDS from any cause

Learn more

ARDS (Acute Respiratory Distress Syndrome) is a severe, life-threatening medical condition characterized by widespread inflammation and fluid accumulation in the lungs. Every year, this condition kills more people than breast and prostate cancer combined. With no approved pharmacotherapy and caused by pneumonia, sepsis and trauma, this is a huge unmet medical need.

Exvastat has created the first stable formulation of imatinib, Impentri™, that can be delivered intravenously. This hugely extends its value as it can be used with patients unable to receive oral treatments due to coma. This aspect transforms our ability to prevent the tragic loss of human life due to ARDS.

Read more
Intravenous therapy
perfect for critical care
Can be administered
without delay
Not blocked by
mechanical ventilation
Does not rely on
GI tract absorption

Our story

In 2008, a woman with life-threatening pulmonary oedema was treated in an Amsterdam hospital…

She was resistant to all the normal therapeutic options, and treated off-label with imatinib, a drug then thought promising for pulmonary hypertension…

The oedema disappeared within 24 hours, leading to the hypothesis that the same drug could be effective in similar conditions, like Acute Respiratory Distress Syndrome (ARDS).

This has now been confirmed in a Phase II proof-of-concept study.

Read more

Partner with us to save lives

Contact us

About Impentri™

Impentri™ is a high impact product that is uniformly effective in a heterogeneous condition. The new treatment is based on the drug's ability to inhibit vascular leak, which drives the pulmonary oedema. It has proven effective in a number of human case reports as well as in vivo models.

ARDS currently lacks any approved pharmaceutical therapy, with treatment limited to supportive ventilatory care. As Impentri™ can significantly reduce the high mortality and incapacitating morbidities caused by ARDS, it will radically reduce the cost of care.

Read more

Latest News

Feb 21, 2022

Long-Term clinical outcome study of CounterCOVID patients published

“Lower mortality rate, better clinical status, and shorter duration of invasive ventilation were observed in hospitalised patients with COVID-19 treated with imatinib during a 90-day follow-up”

Read more

Aug 06, 2021

Further investment and three new appointments announced

Exvastat Ltd (“Exvastat”) receives further investment from Cambridge Innovation Capital and announce expansion of the team with three key new appointments

Read more

Jul 12, 2021

First Patients Enter Clinical Trial of Impentri for COVID-19 ARDS

The Impentri IMI2 consortium are pleased to announce the first patients have entered their clinical trial to investigate the safety and efficacy of intravenous imatinib mesilate (Impentri) in subjects with Acute Respiratory Distress Syndrome induced by COVID-19

Read more
All news